Outcome of Board Meeting

October 30, 2026 Listing Department, Listing Department, National Stock Exchange of India Limited BSE Limited Exchange Plaza, Plot C-1, Block G, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai - 400 051 Mumbai - 400 001 Symbol: MAXHEALTH Scrip Code: 543220 Sub.: Outcome of Board Meeting Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir / Madam, In continuation to our earlier intimation dated October 23, 2026, we wish to inform that the board of directors (“Board”) of the Company at their meeting held today i.e. October 30, 2026, inter-alia, transacted following businesses: Financial Results Approved the unaudited standalone & consolidated financial results (“Financial Results”) of the Company for the quarter and half year ended September 30, 2026, based on the recommendation of Audit Committee. Financial Results together with unmodified limited review reports issued by M/s. S.R. Batliboi & Co. LLP, Chartered Accountants, Statutory Auditors of the Company are enclosed as Annexure - I. Capital expenditure for expansion of Max Super Speciality Hospital, Sector-128, Noida Approved capital expenditure of ~₹93 Crore towards the redevelopment and clinical capacity enhancement programme at Max Super Speciality Hospital, Sector-128, Noida (“MSSH Noida”). MSSH Noida is run and operated by Crosslay Remedies Limited (formerly known as ‘Jaypee Healthcare Limited’), a wholly-owned subsidiary of the Company (“Crosslay”). Details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) are enclosed as Annexure - II. Capital expenditure for expansion of Max Super Speciality Hospital, Vaishali Approved capital expenditure of ~₹97 Crore towards the construction of additional floors at over the existing tower at Max Super Speciality Hospital, Vaishali (“MSSH Vaishali”). MSSH Vaishali is run and operated by Crosslay. Details as required under the SEBI Listing Regulations are enclosed as Annexure - III. Appointment of Senior Management Personnel Approved the appointment of Dr. Dharmender Kumar as Director & Chief - Public Affairs, identified as Senior Management Personnel with effect from November 1, 2026, based on the recommendation of Nomination and Remuneration Committee. Details as required under the SEBI Listing Regulations are enclosed as Annexure - IV. Update on Construction of ~525 bedded hospital at Sector - 56, Gurugram In continuation of our earlier intimation dated May 22, 2024, approved the revision of the project cost to ~₹1,143 Crore and the timeline for completion of the proposed ~525 bedded hospital at Sector - 56, Gurugram to April 2027. The revision in project cost is primarily attributable to changes in façade specifications, additional construction requirements, development of the atrium and enhanced interior fit-outs. All other aspects of the project, other than the revised project cost and completion timeline, remain unchanged. The Board meeting commenced at 12.50 pm (IST) and concluded at 2.35 pm (IST). This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in. Kindly take the same on record. Thanking you Yours truly, For Max Healthcare Institute Limited Dhiraj Aroraa EVP - Company Secretary and Compliance Officer Encl.: As above S.R. Co. LLP 67. Institutional Area BArL1B01 & Sector 44, Gurugram -122 003 Haryana, India Chartered Accountants Tel: +91 124 681 6000 Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Max Healthcare Institute Limited 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Max Healthcare Institute Limited {the "Holding Company"), its subsidiaries and its deemed separate entities, that is 'Silos' over which the Holding Company has control (the Holding Company, its subsidiaries and its deemed separate entities that is 'Silos", together referred to as "the Group") for the quarter ended September 30, 2026 and year to date from April I, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute ofC hartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the Circular No. CIR/CFD/CMD 1/44/2019 dated March 29, 2019, issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the following entities as mentioned in Annexure I. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Comp;mies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of four subsidiaries, whose unaudited interim financial results include total assets of Rs. 33,690 Lakhs as on September 30, 2026, total revenues of Rs. 3,666 Lakhs and Rs. 5,547 Lakhs, total net profit after tax of Rs. 20 Lakhs and Rs. 81 Lakhs, total comprehensive income of Rs. 5 Lakhs and Rs. 68 Lakhs, for the quarter ended September 30, 2026, and the period ended on that date respectively, and net cash inflow of Rs. 8,777 Lakhs for the period from April OI , 2026, to September 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors. S.R. Batlibol g Co LLP, a Limited Llablllty Partnership wi [Showing first 8,000 characters — download PDF for full document]